Int J Mol Sci
Perinatal Research Center, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Published: February 2025
Postnatally, glucagon acutely lowers plasma amino acid (AA) concentrations by stimulating hepatic AA catabolism, but its fetal actions remain unclear. This study tested whether a 2 h fetal glucagon infusion would stimulate hepatic AA catabolism and inhibit placental AA transfer. Late-gestation pregnant sheep (0.9 gestation) underwent surgical, vascular catheterization and received fetal glucagon ( = 8) or vehicle infusions ( = 8) in a crossover design with a 48 h washout period. Nutrient uptake and utilization were assessed during each infusion, and fetal liver and placental tissue were collected post-infusion under hyperglucagonemic ( = 4) or vehicle ( = 4) conditions. Glucagon receptor was identified in fetal hepatocyte and trophoblast cells. Glucagon reduced fetal plasma AA concentrations by 20% ( = 0.0103) and increased plasma glucose by 47% ( = 0.0152), leading to a three-fold rise in fetal plasma insulin ( = 0.0459). Hepatic gene expression associated with AA catabolism and gluconeogenesis increased ( < 0.0500) following glucagon infusion, and hepatic metabolomic analysis showed enrichment in AA metabolism pathways. However, placental AA transfer was unaffected by 2 h fetal glucagon infusions. In conclusion, a 2 h glucagon infusion stimulates hepatic glucose production and enhances AA catabolism in the fetal liver, lowering plasma AA concentrations. The primary acute effects of fetal glucagon are hepatic, as placental AA transfer is unchanged.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3390/ijms26051904 | DOI Listing |
Int J Mol Sci
March 2025
Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
Gestational diabetes mellitus (GDM) is characterized by an inadequate pancreatic β-cell response to pregnancy-induced insulin resistance, resulting in hyperglycemia. The pathophysiology involves reduced incretin hormone secretion and signaling, specifically decreased glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), impairing insulinotropic effects. Pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), impair insulin receptor substrate-1 (IRS-1) phosphorylation, disrupting insulin-mediated glucose uptake.
View Article and Find Full Text PDFInt J Mol Sci
February 2025
Perinatal Research Center, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Postnatally, glucagon acutely lowers plasma amino acid (AA) concentrations by stimulating hepatic AA catabolism, but its fetal actions remain unclear. This study tested whether a 2 h fetal glucagon infusion would stimulate hepatic AA catabolism and inhibit placental AA transfer. Late-gestation pregnant sheep (0.
View Article and Find Full Text PDFJ Mol Endocrinol
March 2025
L Huang, Department of Nutrition, University of California at Davis, Davis, United States.
Somatostatin (Sst) is an inhibitory regulator of many hormones. The prenatal environment impacts offspring's risk to type 2 diabetes in adulthood. However, the effect of maternal Sst deficiency on glucose and insulin metabolism in offspring and metabolic disease risk in their adult life have been poorly understood.
View Article and Find Full Text PDFJ Physiol
February 2025
Laboratory of Molecular Biology of Exercises (LaBMEx), School of Applied Sciences, University of Campinas, Campinas, Brazil.
Clin Med (Lond)
February 2025
School of Medicine, Faculty of Health, Keele University, North Staffordshire, UK; Department of Diabetes & Endocrinology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK. Electronic address:
The prevalence of type 2 diabetes mellitus (T2DM) and obesity is increasing in young adults, posing significant risks around pregnancy. Obesity also impacts on fertility and the co-existence of polycystic ovarian syndrome increases the prevalence of cardiovascular metabolic risk factors. There has been a renewed interest in glucagon-like peptide-1 receptor agonists (GLP-1RA) in this context, due to their multi-dimensional impact on the reproductive axis, as well as their ability to simultaneously target weight loss and glycaemic control.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.